Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCLA-128 in NRG1 fusion-positive solid tumors
jRCT2031210483Phase 2Active, not recruiting
- Sponsor
- Partner Therapeutics, Inc.
- Start
- Dec 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of zenocutuzumab in non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma (PDAC) and Nonhematologic neoplasms, sponsored by Partner Therapeutics, Inc. Primary endpoint: Overall response rate. Started Dec 2020; status: active, not recruiting.
02
Drugs
zenocutuzumab
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031210483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210483.